Stelo CGM for Prediabetes

(CGM Trial)

This trial tests the Stelo continuous glucose monitor (CGM) to determine its effectiveness in helping people with prediabetes manage their blood sugar levels. Participants will either use the Stelo CGM for three months or receive standard care without the device. The trial is ideal for individuals who meet the American Diabetes Association's criteria for prediabetes and have a smartphone compatible with the CGM app. As an unphased trial, it offers participants the chance to contribute to innovative research that could improve prediabetes management.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Stelo Continuous Glucose Monitor (CGM) is safe for adults. The FDA approved it for purchase without a prescription for individuals aged 18 and older, confirming it meets safety standards for general use. Studies have found that this device employs accurate technology developed by Dexcom, a leader in glucose monitoring for over 25 years.

Although the Stelo CGM is generally safe, it is not recommended for individuals who frequently experience hypoglycemia, a condition where blood sugar levels drop too low. Most users, however, find the device easy to use and reliable for monitoring glucose levels.

Unlike traditional treatments for prediabetes that often focus on lifestyle changes like diet and exercise or medications like metformin, the Stelo CGM device offers a continuous glucose monitoring approach. This device provides real-time glucose level tracking, which can empower users with immediate feedback on how their lifestyle choices impact their glucose levels. Researchers are excited because this could lead to more proactive and personalized management of prediabetes, potentially preventing the progression to type 2 diabetes more effectively than current methods.

This trial will compare the Stelo CGM device with standard care for individuals with prediabetes. Research has shown that continuous glucose monitors (CGMs) like the Stelo can help people with diabetes better control their blood sugar. Studies have found that using a CGM can improve blood sugar levels, such as lowering hemoglobin A1c, which measures long-term blood sugar control. The Stelo device demonstrates a 93% accuracy rate compared to standard lab tests. For those with prediabetes, the goal is to use a CGM to manage blood sugar and prevent diabetes. Overall, CGMs are associated with greater satisfaction and improved blood sugar management.¹⁵⁶⁷⁸